Gaius Therapeutics, Inc,

Biotechnology · SAN DIEGO, CA

BiotechnologySEC Form D

Gaius Therapeutics, Inc, filed a Form D with the U.S. Securities and Exchange Commission on May 14, 2026, reporting $60,000 raised toward a $250,000 offering.

Incorporated in Delaware and based in SAN DIEGO, CA, it operates in the Biotechnology sector.

Companies file a Form D within 15 days of the first sale of securities in a private offering under Regulation D — an early, public signal that Gaius Therapeutics, Inc, has raised capital from private investors.

Browse more recently funded companies in Biotechnology.

Executives & Directors

  • Jesse Joseph SolvasonExecutive Officer · Director
  • Adam KlieExecutive Officer
  • Javid AceilExecutive Officer
  • Ben WangDirector
  • Christopher EmigDirector
  • Michon PinnixDirector

Recently funded in Biotechnology

Other companies that recently filed a Form D

$3.2MRaised

Goldenrod Therapeutics, Inc.

BiotechnologyHOUSTON, TX
May 26, 2026View SEC Form D
$10.0MRaised

Human Biotech, Inc.

BiotechnologyCAMBRIDGE, MA
May 22, 2026View SEC Form D
$1.0MRaised

Optimeos Life Sciences, Inc.

BiotechnologyPRINCETON, NJ
May 22, 2026View SEC Form D
$2.5MRaised

BioStem Technologies, Inc.

BiotechnologyPOMPANO BEACH, FL
May 21, 2026View SEC Form D
$1.6MRaised

Biolexis Therapeutics Inc.

BiotechnologyLEHI, UT
May 20, 2026View SEC Form D
Gaius Therapeutics, Inc, raised $60.0K — SEC Form D